COVID-19 Antigen Test
Result in 10 minutes at the point of care
The MARK-B™ COVID-19 Ag S test is a electrochemical sandwich immunoassay that is used with the MARK-B™ 1 analyzer intended for the qualitative detection of the spike protein antigen from SARS-CoV-2 in nasopharyngeal swab specimens.
The MARK-B™ COVID-19 Antigen Test allows fast diagnosis with results in 10 minutes in a variety of locations such as physicians' offices, urgent care clinics and other POC locations.
Results in 10 minutes
The MARK-B™ 1 analyzer offers an easy-to-use interface, customizable settings, flexible workflow and connectivity. The MARK-B™ 1 analyzer removes the operator variability associated with interpreting visually read test results.
The tests results are reported automatically on the screen and can be stored in analyze, optionally printed on an external printer.
COVID-19 Antigen S Test
Limit of Detection:
TCID 2.4 x10 per mL
Qualitative detection of SARS-CoV-2 spike proteins
Sensitivity 98.5% , Specificity 98.5 %
Fast results within 10 mins
Specimen : nasopharyngeal swab
Fully automated analysis
Once inserted into the instrument, the sample is separated into plasma by our patent technology.
In succession, the electrochemical analysis process begins.
No need for pre-processing
Quick turnaround 10mins
by electrochemical method
MARK-B™ utilizes MESIA,
a patented technology of BBB inc.
Published Journal Paper
“MESIA: Magnetic force-assisted electrochemical sandwich immunoassays for quantification of prostate-specific antigen in human serum”
- <Analytica Chimica Acta>, March, 2019
_ PhD. Hyundoo Hwang, Leader of BBB R&D Center
High expandability in test portfolio
*Not available for sale
*Scheduled to release in 2020
Cloud server to communicate with MARK-B™ test results
POCT1-A2 protocol, HL7, FHIR® to communicate with DMS
Android based Analyzer software
**Depends on the analyte